Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:15 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1345–1368 of 7,459 matching trials from the live ClinicalTrials.gov search.

Filters: Denver, Colorado Clear all

Conditions: Cystic Fibrosis
Interventions: Not listed
Lead sponsor: Nicole Hamblett; Other
Eligibility: 12 Years and older
Enrollment: 987 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 80
States / cities: Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 69 more

Conditions: Asthma
Interventions: Aerovant, placebo; Drug · Other
Lead sponsor: Aerovance, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 424 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 38
States / cities: Mobile, Alabama • Scottsdale, Arizona • Huntington Beach, California + 31 more

Conditions: Multiple Myeloma
Interventions: Daratumumab IV, Lenalidomide, Dexamethasone, Daratumumab SC; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 737 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 83
States / cities: Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 80 more

Conditions: Pancreatic Cancer
Interventions: Registry; Other
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2030
U.S. locations: 11
States / cities: Birmingham, Alabama • San Diego, California • Denver, Colorado + 8 more

Conditions: Inguinal Hernia
Interventions: Regional Anesthesia, General Anesthesia; Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: Up to 60 Weeks
Enrollment: 643 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2018
U.S. locations: 10
States / cities: Aurora, Colorado • Chicago, Illinois • Iowa City, Iowa + 7 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Alectinib; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 39
States / cities: Birmingham, Alabama • Irvine, California • La Jolla, California + 32 more

Conditions: Dravet Syndrome (DS), Lennox Gastaut Syndrome (LGS)
Interventions: Soticlestat; Drug
Lead sponsor: Takeda; Industry
Eligibility: 2 Years to 56 Years
Enrollment: 352 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 26
States / cities: Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 19 more

Conditions: Cystic Fibrosis, CF, Lung Infection, Pseudomonas Aeruginosa
Interventions: Aztreonam for Inhalation (AI), Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 13 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 20
States / cities: Los Angeles, California • Orange, California • San Diego, California + 17 more

Conditions: Uterine Fibroids
Interventions: 12.5 mg Proellex, 25 mg Proellex, Placebo; Drug
Lead sponsor: Repros Therapeutics Inc.; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 16
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tuscon, Arizona + 9 more

Conditions: HIV Infections
Interventions: Aldesleukin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2000
U.S. locations: 15
States / cities: San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 11 more

Conditions: Chronic Kidney Disease
Interventions: Verinurad, Allopurinol, Placebo for Verinurad, Placebo for Allopurinol; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 861 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 54
States / cities: Huntsville, Alabama • Bakersfield, California • Canyon Country, California + 45 more

Conditions: AML, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, CMML, Myelodysplastic Syndromes, High-risk Myelodysplastic Syndrome, MDS
Interventions: APG-115, 5-azacitidine; Drug
Lead sponsor: Ascentage Pharma Group Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 8
States / cities: Gilbert, Arizona • Denver, Colorado • Durham, North Carolina + 5 more

Conditions: Diabetes Mellitus
Interventions: Inhaled Insulin, Subcutaneous insulin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 35 Years to 75 Years
Enrollment: 635 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 69
States / cities: Phoenix, Arizona • Tucson, Arizona • Fresno, California + 57 more

Conditions: HER2-positive Breast Cancer
Interventions: tucatinib, placebo, T-DM1; Drug
Lead sponsor: Seagen, a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 466 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 321
States / cities: Mobile, Alabama • Gilbert, Arizona • Goodyear, Arizona + 180 more

Conditions: Asthma
Interventions: Mometasone 220mcg BID, Tiotropium Respimat 5mcg QD, Placebo; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 12 Years and older
Enrollment: 295 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 25
States / cities: Tucson, Arizona • San Francisco, California • Denver, Colorado + 13 more

Conditions: Ischemia-Reperfusion Injury, Lung Transplantation
Interventions: Repertaxin, Placebo; Drug · Other
Lead sponsor: Dompé Farmaceutici S.p.A; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 5
States / cities: Los Angeles, California • Denver, Colorado • St Louis, Missouri + 2 more

Conditions: Polycystic Kidney, Autosomal Dominant
Interventions: Tesevatinib; Drug
Lead sponsor: Kadmon, a Sanofi Company; Industry
Eligibility: 18 Years to 62 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 11
States / cities: Los Angeles, California • Denver, Colorado • Kansas City, Kansas + 8 more

Conditions: Iron Deficiency, Iron Deficiency Anemia
Interventions: Vitamin E, Placebo; Drug · Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 9 Months to 2 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions: carboplatin, paclitaxel, topotecan hydrochloride; Drug
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 46
States / cities: Birmingham, Alabama • Los Angeles, California • Los Gatos, California + 39 more

Conditions: Infection, Human Immunodeficiency Virus, HIV Infections
Interventions: CAB Oral Tablets, CAB LA, ABC/3TC Oral tablets, RPV Oral Tablets, HAART, RPV; Drug · Other
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 309 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 15
States / cities: Birmingham, Alabama • Bakersfield, California • Beverly Hills, California + 12 more

Conditions: Leukemia, Myeloid, Chronic Phase
Interventions: Imatinib mesylate; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 476 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 50
States / cities: Mobile, Alabama • Berkeley, California • Campbell, California + 35 more

Conditions: Delirium, Critical Illness
Interventions: Haloperidol; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: HIV Infections, Peripheral Nervous System Disease
Interventions: Amitriptyline hydrochloride, Amitriptyline hydrochloride placebo, Point acupuncture; Drug · Procedure
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 1997
U.S. locations: 11
States / cities: San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 7 more

Conditions: Heart Failure
Interventions: IASD System II implant, intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE); Device · Other
Lead sponsor: Corvia Medical; Industry
Eligibility: 40 Years and older
Enrollment: 608 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 44
States / cities: Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 36 more

Search by objective public record fields.

Impact of Discontinuing Chronic Therapies in People With Cystic Fibrosis on Highly Effective CFTR Modulator Therapy

A Study of the Treatment-Sparing Effects of AEROVANT™ AER 001 Inhalation Powder in Asthma Patients, AEROTRIAL

Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma

American Hepato-Pancreato-Biliary Association (AHPBA) Pancreatic Irreversible Electroporation (IRE) Registry

A Multi-site Randomized Controlled Trial Comparing Regional and General Anesthesia for Effects on Neurodevelopmental Outcome and Apnea in Infants

A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)

A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or Lennox-Gastaut Syndrome

Aztreonam for Inhalation (AI) in Patients With Cystic Fibrosis & P. Aeruginosa Infection

Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids

A Study to Evaluate the Effects of Giving Proleukin (rIL-2) to HIV-Positive Patients With CD4 Counts Greater Than 300 Cells/mm3

A Study of Verinurad and Allopurinol in Patients With Chronic Kidney Disease and Hyperuricaemia

A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS

Efficacy and Safety of Inhaled Insulin Compared With Subcutaneous Human Insulin Therapy in Adults With Type 2 Diabetes

A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

Steroids In Eosinophil Negative Asthma

Repertaxin in Prevention of Primary Graft Dysfunction After Lung Transplantation

A Safety, Pharmacokinetic & Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease

Enhancing Treatment of Iron Deficiency and Iron Deficiency Anemia With an Antioxidant, Vitamin E

Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer

A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects

Efficacy of 400 Mg Versus 800 Mg Imatinib in Chronic Myeloid Leukemia in Chronic Phase Patients - TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity)

Pilot Study of Haloperidol to Treat Critical Illness Delirium

The Efficacy of a Standardized Acupuncture Regimen and Amitriptyline Compared With Placebo as a Treatment for Pain Caused by Peripheral Neuropathy in HIV-Infected Patients

REDUCE LAP-HF TRIAL II